Denmark· DK-28107381325

Rezolsta

A darunavir and cobicistat product containing cobicistat, darunavirethanolat, registered in Denmark by Janssen-Cilag International NV. The same ATC class is registered in 12 of our 19 countries.

ATC J05AR14

Checked against Danish Medicines Agency (Denmark) on

Informational only — not a medical device.

SOURCE REGISTER · DKDanish Medicines Agency (Denmark)normalisedRezolstaATCJ05AR14REGISTER NO.DK-28107381325PACKS LISTED1CHECKEDSeptember 30, 2026

Where it is registered

Darunavir and cobicistat is registered in 12 of 19 countries.

Countries holding a registration under ATC J05AR14 (darunavir and cobicistat), each read from that country’s own register.

  • This record: Denmark, from Danish Medicines Agency (Denmark)
  • 7 of them publish a price we can compare per daily dose

Darunavir and cobicistat · ATC J05AR14

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Danish Medicines Agency (Denmark)
Active substance
Cobicistat, Darunavirethanolat
Manufacturer
Janssen-Cilag International NV
Country
Denmark (DK)
ATC code
J05AR14
ATC class
Darunavir and cobicistat
Reimbursed
Not published by this register
Source register
Danish Medicines Agency (Denmark)
Last checked
September 30, 2026

Packs & prices · 1

  • dk_varenummer
    28107381325

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

541 interactions on record for darunavir and cobicistat.

Graded by severity as the source publishes them — 243 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Darunavir and cobicistat · interactions on record

541 records

  • 243 severe
  • 277 moderate
  • 21 minor

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • LoperamideA07DA03severe
  • EluxadolineA07DA06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cd90e932-374a-4fc6-a7b7-1d44951be43c
GET /v1/drugs/cd90e932-374a-4fc6-a7b7-1d44951be43c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "filmovertrukne tabletter",
  "source": "dkma",
  "strength": "600 mg + 90 mg",
  "auth_role": "MOD",
  "dk_drugid": "28107381325",
  "substance": "Cobicistat, Darunavirethanolat",
  "auth_procedure": "Central",
  "in_medicinpriser": false,
  "registration_date_serial": "41962"
}

See everything about darunavir and cobicistat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.